Table 1.

Principal Anthracycline-containing regimens used in clinical practice according to cancer type, timing and schedule, and number of cycles

Cancer and Regimen	Anthracycline Used	Timing and Schedule	Number of Cycles	Doxorubicin Equivalent Dose15
Breast Cancer
Early Breast Cancer
Neoadjuvant/Adjuvant Setting			4
AC/EC	Adriamycin	60 mg/m2 day 1-every 21 days		240 mg/m2
	Epirubicin	90 mg/m2 day 1-every 21 days		≈240 mg/m2
A/E->CMF	Adriamycin	75 mg/m2 day 1-every 21 days	4	300 mg/m2
	Epirubicin	90 mg/m2 day 1-every 21 days		≈240 mg/m2
CAF/CEF	Adriamycin	30 mg/m2, days 1, 8-every 28 days	6	360 mg/m2
	Epirubicin	60 mg/m2, days 1, 8-every 28 days		≈480 mg/m2
FAC/FEC	Adriamycin	50-60 mg/m2, day 1-every 21 days	6	360 mg/m2
	Epirubicin	75-100 mg/m2, day 1-every 21 days		≈400 mg/m2
AC/EC/FEC->weekly Paclitaxel (12 weeks)			4	240 mg/m2
AC->weekly Docetaxel (4 weeks)			4	240 mg/m2
FEC100 > Docetaxel	Epirubicin	100 mg/m2, day 1-every 21 days	3	≈200 mg/m2
TAC	Adriamycin	50 mg/m2, day 1-every 21 days	6	300 mg/m2
Advanced/Metastatic Breast Cancer
Anthracyclines+Taxanes	The association Anthracyclines (epirubicin, adriamycin)+Taxanes (paclitaxel, docetaxel, nabpaclitaxel) is preferred in patients with advanced PD-L1-, gBRCA1/2- TNBC, in particular in those without previous exposition to anthracyclines or with long disease-free interval.

Cancer and Regimen	Anthracycline Used	Timing and Schedule	Number of Cycles	Doxorubicin Equivalent Dose
Acute Myeloid Leukemia
Ara-C+ Daunorubicin/Idarubicin	Daunorubicin	45 mg/m2, days 1 to 3		≈110 mg/m2
	Idarubicin	12 mg/m2, days 1 to 3		≈180 mg/m2
Acute Lymphoblastic Leukemia
CALGB 8811	Daunorubicin	45 mg/m2, days 1 to 3		≈110 mg/m2
	Adriamycin for late intensification	30 mg/m2, days 1, 8, 15		90 mg/m2
hyper-CVAD	Adriamycin	50 mg/m2, day 4		50 mg/m2
Hodgkin Lymphoma
ABVD	Adriamycin	25 mg/m2, day 1-15, every 28 days	3-6	150 mg/m2-300 mg/m2
BEACOPP			8 6
Standard	Adriamycin	25 mg/m2, day 1, every 21 days		200 mg/m2
Dose-Escalated	Adriamycin	35 mg/m2, day 1 every 21 days		210 mg/m2
Diffuse Large B Cell Lymphoma
R-CHOP	Adriamycin	50 mg/m2, day 1, every 21 days	6-8	300-400 mg/m2
Sarcomasa
STS
Adriamycin alone or in combination with Ifosfamideb	Adriamycin	75 mg/m2, day 1, every 14/21 days	6	450 mg/m2
Osteosarcoma
High-dose ifosfamide, methotrexate, cisplatin and adriamycin	Adriamycin	75 mg/m2 in neoadjuvant setting 90 mg/m2	2	255 mg/m2
Ewing Sarcoma
Vincristine, cyclophosphamide, ifosfamide, etoposide and adriamycin	Adriamycin	60 mg/m2 (20 mg/m2 day 1, 2, 3 repeated every 14 days)	6	360 mg/m2

A = adriamycin; ABVD = doxorubicin + bleomycin + vinblastine + dacarbazine; AC = adriamycin + cyclophosphamide; BEACOPP = bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone; CAF = cyclophosphamide + adriamycin + 5-fluorouracil; CALGB 8811 = daunorubicin + vincristine + prednisone + pegaspargase + cyclophosphamide; CEF = cyclophosphamide + epirubicin + fluorouracil; CMF = cyclophosphamide + methotrexate + fluorouracil; E = epirubicin; EC = epirubicin+cyclophosphamide; FAC = fluorouracil + adriamycin + cyclophosphamide; FEC = fluorouracil + epirubicin + cyclophosphamide; hyper-CVAD = fractionated cyclophosphamide + vincristine + doxorubicin + dexamethasone; PD-L1 = programmed death-ligand 1; R-CHOP = rituximab-cyclophosphamide + doxorubicin + vincristine + prednisone; STS = soft tissue sarcoma; TAC = docetaxel + Adriamycin + cyclophosphamide; TNBC = triple-negative breast cancer.

^aWith due exceptions, in patients affected by sarcoma, dose intensification by interval compression has demonstrated increased benefit than standard 3-week intervals, with no increase in toxicity.

^bRegimen used in advanced or metastatic STS. For anthracycline toxicity equivalence ratio¹⁵, doxorubicin: 1, daunorubicin: 0.833, idarubicin: 5, epirubicin: 0.67.